Unknown

Dataset Information

0

A highly potent antibody effective against SARS-CoV-2 variants of concern.


ABSTRACT: Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral variants with increased transmission efficiency, resistance to marketed therapeutic antibodies, and reduced sensitivity to vaccine-induced immunity. Here, we screen B cells from COVID-19 donors and identify P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar neutralizing activity against all SARS-CoV-2 variants of concern (VOCs) identified to date. Structural characterization of P5C3 Fab in complex with the spike demonstrates a neutralizing activity defined by a large buried surface area, highly overlapping with the receptor-binding domain (RBD) surface necessary for ACE2 interaction. We further demonstrate that P5C3 shows complete prophylactic protection in the SARS-CoV-2-infected hamster challenge model. These results indicate that P5C3 opens exciting perspectives either as a prophylactic agent in immunocompromised individuals with poor response to vaccination or as combination therapy in SARS-CoV-2-infected individuals.

SUBMITTER: Fenwick C 

PROVIDER: S-EPMC8452523 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8637776 | biostudies-literature
| S-EPMC9653380 | biostudies-literature
| S-EPMC9188817 | biostudies-literature
| S-EPMC8710476 | biostudies-literature
| S-EPMC9514956 | biostudies-literature
| S-EPMC9762654 | biostudies-literature
| S-EPMC10449910 | biostudies-literature
| S-EPMC9711903 | biostudies-literature
| S-EPMC9528872 | biostudies-literature
| S-EPMC10749193 | biostudies-literature